biostudies-literatureWei YMedical Research Councilwellcome trustWellcome TrustAcademy of Medical Sciences385https://www.ebi.ac.uk/biostudies/studies/S-EPMC8487486biostudies-literatureUnknown14(1)<h4>Objective</h4>The objective of this study was to employ ensemble clustering and tree-based risk model approaches to identify interactions between clinicogenomic features for colorectal cancer using the 100,000 Genomes Project.<h4>Results</h4>Among the 2211 patients with colorectal cancer (mean age of diagnosis: 67.7; 59.7% male), 16.3%, 36.3%, 39.0% and 8.4% had stage 1, 2, 3 and 4 cancers, respectively. Almost every patient had surgery (99.7%), 47.4% had chemotherapy, 7.6% had radiotherapy and 1.4% had immunotherapy. On average, tumour mutational burden (TMB) was 18 mutations/Mb and 34.4%, 31.3% and 25.7% of patients had structural or copy number mutations in KRAS, BRAF and NRAS, respectively. In the fully adjusted Cox model, patients with advanced cancer [stage 3 hazard ratio (HR)  =BMC research notesApplication of ensemble clustering and survival tree analysis for identifying prognostic clinicogenomic features in patients with colorectal cancer from the 100,000 Genomes Project.PMC8487486SBF006\1084204841/Z/16/ZHDR-9004MR/S006753/1Papachristou NSavage KFowler TChan GCWilliams EPullinger JLopez FJWalsh EMaleady-Crowe FGenomics England Research ConsortiumLahnstein LHubbard TJPWelland MJStuckey AChang WHSieghart ACaulfield MJHamblin AMueller MO'Donovan PAmbrose JCScott RHMueller STucci AMoutsianas LBleda MLeigh SEAPatch CThomas ERABrittain HJones LJArumugam PKasperaviciute DHenderson SPereira MBRogers TWei YBoardman-Pretty FKayikci MThompson SRMurugaesu NLeong IUSKousathanas AWitkowska KTanguy MLai AGSmith SCJackson RGiess ARendon ASosinsky APerez-Gil DNeed ACSawant KBoustred CRSiddiq AOdhams CARahim TWood SMfalseApplication of ensemble clustering and survival tree analysis for identifying prognostic clinicogenomic features in patients with colorectal cancer from the 100,000 Genomes Project.<h4>Objective</h4>The objective of this study was to employ ensemble clustering and tree-based risk model approaches to identify interactions between clinicogenomic features for colorectal cancer using the 100,000 Genomes Project.<h4>Results</h4>Among the 2211 patients with colorectal cancer (mean age of diagnosis: 67.7; 59.7% male), 16.3%, 36.3%, 39.0% and 8.4% had stage 1, 2, 3 and 4 cancers, respectively. Almost every patient had surgery (99.7%), 47.4% had chemotherapy, 7.6% had radiotherapy and 1.4% had immunotherapy. On average, tumour mutational burden (TMB) was 18 mutations/Mb and 34.4%, 31.3% and 25.7% of patients had structural or copy number mutations in KRAS, BRAF and NRAS, respectively. In the fully adjusted Cox model, patients with advanced cancer [stage 3 hazard ratio (HR)  =2021-01-01T00:00:00Z2021 Oct2025-06-01T00:55:28.46Z2025-06-01T00:55:28.46ZS-EPMC84874863460057510.1186/s13104-021-05789-0